Craft
LianBio

LianBio

Market Capitalization

$230.6 M

2022-09-21

LianBio Summary

Company summary

Overview
LianBio is a biopharmaceutical company that designs and provides innovative drugs and treatments for oncology and cardiology diseases. The company develops nine product candidates across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. Its late-stage, clinically validated pipeline is comprised of five product candidates: mavacamten, TP-03, NBTXR3, infigratinib, and LYR-210.
Type
Public
Founded
2019
HQ
Princeton, NJ, US | view all locations
Website
https://lianbio.com/
Cybersecurity rating
Sectors

Key people

  • Yizhe Wang

    Yizhe Wang, Chief Executive Officer and Director

  • Debra Yu

    Debra Yu, President and Chief Strategy Officer

  • Yi Larson

    Yi Larson, Chief Financial Officer

  • Brianne Jahn

    Brianne Jahn, Chief Business Officer

LocationsView all

2 locations detected

  • Princeton, NJ HQ

    United States

    103 Carnegie Center Dr Suite 215

  • Shanghai, Shanghai Shi

    China

    1155 Fangdian Rd, Shi Ji Gong Yuan, Pudong Xinqu

LianBio Financials

Summary financials

Net income (Q2, 2022)
($42.4M)
Cash (Q2, 2022)
$134.3M
EBIT (Q2, 2022)
($43.1M)
Enterprise value
$101.7M

Footer menu